226 related articles for article (PubMed ID: 26281907)
1. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
[TBL] [Abstract][Full Text] [Related]
2. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Tolcher AW; Appleman LJ; Shapiro GI; Mita AC; Cihon F; Mazzu A; Sundaresan PR
Cancer Chemother Pharmacol; 2011 Apr; 67(4):751-64. PubMed ID: 20521052
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
Sunakawa Y; Furuse J; Okusaka T; Ikeda M; Nagashima F; Ueno H; Mitsunaga S; Hashizume K; Ito Y; Sasaki Y
Invest New Drugs; 2014 Feb; 32(1):104-12. PubMed ID: 23553067
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
8. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
[TBL] [Abstract][Full Text] [Related]
9. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
11. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
13. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
Chan SL; Ma BB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
[TBL] [Abstract][Full Text] [Related]
14. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.
Zimmermann T; Höchel J; Becka M; Boettger MK; Rohde B; Schug B; Kunert KS; Donath F
Br J Clin Pharmacol; 2018 May; 84(5):865-875. PubMed ID: 29315699
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI
Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186
[TBL] [Abstract][Full Text] [Related]
16. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
17. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
[TBL] [Abstract][Full Text] [Related]
20. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE; Bolejack V; Ryan CW; Ganjoo KN; Loggers ET; Chawla S; Agulnik M; Livingston MB; Reed D; Keedy V; Rushing D; Okuno S; Reinke DK; Riedel RF; Attia S; Mascarenhas L; Maki RG
J Clin Oncol; 2019 Jun; 37(16):1424-1431. PubMed ID: 31013172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
